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ABSTRACT: Coronaviruses (CoVs) cause numerous dis-
eases, including Middle East respiratory syndrome and severe
acute respiratory syndrome, generating signiﬁcant health-
related and economic consequences. CoVs encode the
nucleocapsid (N) protein, a major structural protein that
plays multiple roles in the virus replication cycle and forms a
ribonucleoprotein complex with the viral RNA through the N
protein’s N-terminal domain (N-NTD). Using human CoV-
OC43 (HCoV-OC43) as a model for CoV, we present the 3D
structure of HCoV-OC43 N-NTD complexed with ribonu-
cleoside 5′-monophosphates to identify a distinct ribonucleotide-binding pocket. By targeting this pocket, we identiﬁed and
developed a new coronavirus N protein inhibitor, N-(6-oxo-5,6-dihydrophenanthridin-2-yl)(N,N-dimethylamino)acetamide
hydrochloride (PJ34), using virtual screening; this inhibitor reduced the N protein’s RNA-binding aﬃnity and hindered viral
replication. We also determined the crystal structure of the N-NTD−PJ34 complex. On the basis of these ﬁndings, we propose
guidelines for developing new N protein-based antiviral agents that target CoVs.
■ INTRODUCTION
Coronaviruses (CoVs) are a large group of RNA viruses with
single-stranded RNA genomes that cause various upper and
lower respiratory tract infections in both humans and
animals.1,2 The human coronavirus strains OC43 and 229E
(HCoV-OC43 and HCoV-229E) were identiﬁed in the 1960s.3
Between 2003 and 2004, the severe acute respiratory syndrome
coronavirus (SARS-CoV) caused a worldwide epidemic and
had a signiﬁcant economic impact in the countries aﬀected by
the outbreak.4 In 2004, another alphacoronavirus (HCoV-
NL63) was isolated from a 7-month-old child in the
Netherlands suﬀering from bronchiolitis and conjunctivitis.5
In 2005, Woo et al. discovered the novel betacoronavirus
HKU1 in patients with respiratory tract infections.6 Recently,
the Middle East respiratory syndrome coronavirus (MERS-
CoV) was found in patients with severe acute respiratory tract
infections in the Middle East. As is true for all coronavirus
infections, there is no currently available eﬃcacious therapy.
The CoVs have several conserved structural proteins: the
matrix (M), the small envelope (E) proteins, the trimeric spike
(S) glycoproteins, and the nucleocapsid (N) proteins.7 Some
variants have a third glycoprotein, HE (hemagglutinin esterase),
which is present in most betacoronaviruses.8,9 The N protein is
a major structural CoV protein that serves multiple purposes,
such as packaging the RNA genome into helical ribonucleo-
proteins, modulating host cell metabolism, and regulating viral
RNA synthesis during replication and transcription.10,11 The N
protein binds to the viral RNA genome, forming a long helical
nucleocapsid structure or ribonucleoprotein (RNP) complex.12
In situ cross-linking and immunological experiments revealed
that the RNP formation is critical for maintaining an ordered
RNA conformation suitable for replicating and transcribing the
viral genome.10,13 Other studies implicate the N protein in the
regulation of cellular processes, including actin reorganization,
host cell cycle progression, and apoptosis.14−16 The N protein
is capable of inducing protective immune responses against
CoV and is a key antigen for developing a sensitive diagnostic
assay.17
Coronavirus N proteins contain three domains: an N-
terminal RNA-binding domain (NTD), a C-terminal dimeriza-
tion domain (CTD), and a poorly structured central Ser/Arg
(SR)-rich linker. Previous studies have revealed that the N- and
C-terminal domains of the CoV N proteins are responsible for
RNA binding and oligomerization, respectively.18−20 The
central region of the N protein has also been shown to contain
an RNA-binding region and primary phosphorylation sites.21,22
The crystal structures of several CoV N-NTDs, including those
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encoded by SARS,23 infectious bronchitis virus (IBV),24,25
HCoV-OC43,20 and mouse hepatitis virus (MHV)26 have been
solved. Additionally, several critical residues have been
identiﬁed for RNA binding and virus infectivity in the N-
terminal domain of coronaviral N proteins.23,26−28 However,
the structural and mechanistic basis for RNA binding and RNP
formation remains largely unknown. Understanding these
aspects should facilitate the discovery of agents that speciﬁcally
block the formation of RNP during CoV genome replication.
We report the crystal structures of HCoV-OC43 N-NTD
complexed with ribonucleoside 5′-monophosphates as a model
for understanding the molecular interactions that govern CoV
Table 1. Data Collection and Reﬁnement Statistics for HCoV-OC43 N-NTD−AMP and HCoV-OC43 N-NTD−PJ34 Crystals
HCoV-OC43 N-NTD−AMP HCoV-OC43 N-NTD−PJ34
PDB code 4LI4 4KXJ
space group P65 P65
resolution (Å) 30−1.71 (1.77−1.71)a 30−2.65 (2.74−2.65)a
wavelength (Å) 1.00000 1.00000
a = b (Å) 81.919 81.684
c (Å) 42.892 42.950
no. of obsd reﬂns 124447 33506
no. of unique reﬂns 17943 4854
completeness (%) 97.8(100.0)a 99.7(99.8)a
Rmerge (%) 2.6(16.4)
a 8.2(42.8)a
I/σ(I) 55.0(12.64)a 26.4(5.7)a
reﬁnement
no. of reﬂns 17501 4235
Rwork (95% data) 0.22 0.18
Rfree (5% data) 0.25 0.22
bond lengths (Å) 0.008 0.013
bond angles (deg) 1.485 2.032
no. of protein atoms
mean B value (Å2) 33.54 32.35
no. of ligand atoms
mean B value (Å2) 20.24 24.09
no. of water molecules
mean B value (Å2) 37.63 29.3
Ramachandran statistics (%)
most favored region 94.5 91.5
generally allowed region 2.4 6.2
others 3.1 2.3
aValues in parentheses are for the highest resolution shells.
Figure 1. Structural overview of the HCoV-OC43 N-NTD−AMP complex. (A) Ribbon representation of HCoV-OC43 N-NTD with AMP depicted
as a stick structure. (B) Electrostatic surface of the OC43 N-NTD−AMP complex. Blue denotes positive charge potential, while red indicates
negative charge potential. (C) Map of the conserved surfaces of selected CoV N-NTDs (see Figure S1, Supporting Information).
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N-NTD binding to RNA. We also describe the structure of
HCoV-OC43 N-NTD complexed with a new N protein
inhibitor, N-(6-oxo-5,6-dihydrophenanthridin-2-yl)(N,N-
dimethylamino)acetamide hydrochloride (PJ34), and demon-
strate the ability of PJ34 to interfere with both the RNA-
binding activity of the N protein and virus replication. Our
ﬁndings will aid in the development of new drugs that interfere
with viral N proteins and viral replication in HCoVs.
■ RESULTS
Cocrystal Structure of the HCoV-OC43 N-NTD with
AMP. We were unable to ﬁnd any previous reports describing
the atomic structure of CoV N protein−RNA complexes. To
begin to elucidate how RNA and the N protein interact, we
determined the crystal structure of HCoV-OC43 N-NTD
complexed with AMP. The complete statistics for the data
collection and reﬁnement of HCoV-OC43 N-NTD complexed
with AMP are summarized in Table 1. The complex contained
one ribonucleoside 5′-monophosphate-binding site alongside
two β strands (β2 and β3) (Figure 1A). As with apo HCoV-
OC43 N-NTD, the HCoV-OC43 N-NTD complexes all
contain a core located within amino acids 105−120 that
comprises ﬁve β strands, one α helix, and a disordered loop that
extends away from the core. The ﬂexible loop region lies
between β2 and β3 (residues 115−117) and exhibits a low
electron density in the initial 2Fo−Fc map. The AMP base was
inserted into a hole in the N-NTD that was almost
perpendicular to the phosphate moiety (Figure 1B,C). The
phosphate group was bound to a basic and conserved 5′-
phosphate-binding site that contained the largest positively
charged region on the N-NTD surface. The HCoV-OC43 N-
NTD has the same folding pattern as is found in the SARS-
CoV, IBV, and MHV N-NTD;20 however, the positions of the
secondary structural elements and loops vary between the
species.
AMP binding to the N-NTD is clearly unambiguously
deﬁned in the resulting electron density maps provided in
Figure 2A. AMP shows a temperature factor of about 20 Å2,
compared with an average overall temperature factor of around
35 Å2. Figure 2B reveals the detailed interactions between the
AMP and HCoV-OC43 N-NTD. The amino acid composition
of this binding site includes Ser 64, Gly 68, Arg 122, Tyr 124,
Tyr 126, and Arg 164. The positively charged group in the Arg
122 side chain provides an ionic interaction with the AMP
Figure 2. Crystal structure of HCoV-OC43 N-NTD complexed with AMP. (A) Unbiased diﬀerences in the AMP electron density contoured at 2.9σ.
(B) Detailed stereoview of the interactions at the AMP-binding site. The AMP molecule binds to this site via Ser 64, Gly 68, Arg 122, Tyr 124, Tyr
126, and Arg 164. The dotted green lines indicate hydrogen bonds. The red dashed lines indicate ionic interactions. (C) Schematic diagram of the
AMP bound to the HCoV-OC43 N-NTD. The hydrogen-bonding interactions mediated by the side- and main-chain atoms are displayed as solid
and dashed green lines, respectively. The ionic interactions mediated by the side-chain atoms are displayed as dashed red lines. The stacking
interactions mediated by the side-chain atoms are indicated by the solid orange lines. (D) Structural superimposition of the native HCoV-OC43 N-
NTD (green) with HCoV-OC43 N-NTD−AMP (cyan) at the residues involved in the AMP binding.
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monophosphate with a distance of 3.8 Å, whereas the Gly 68
backbone forms hydrogen bonds with the monophosphate
group in the AMP with a distance of 2.4 Å. Additionally, the
carbonyl oxygen and amide nitrogen of the Ser 64 backbone
form hydrogen bonds with the ribose 2′-hydroxyl substituents
and N7 of the base with distances of 3.0 and 2.7 Å, respectively.
Tyr 124 is located on the surface of the N protein in the
HCoV-OC43 N-NTD and is directly involved in the
interactions with the AMP base through π−π stacking. The
phenolic hydroxyl group substituent on Tyr 126 forms
hydrogen bonds with the sixth amino groups present in the
AMP adenine ring with a distance of 3.1 Å. Hydrogen bonds
also form between the 2′-hydroxyl group of the AMP ribose
and the Arg 164 side chain. The Arg 122, Tyr 124, Tyr 126, and
Arg 164 side chains generate a distinct ribonucleotide-binding
pocket and interact with the ribonucleoside 5′-monophosphate
via hydrogen bonding, ionic bonding, and π−π stacking forces
(Figure 2C). These amino acids are sequentially and
structurally conserved in other HCoV N proteins (Figure S2,
Supporting Information); therefore, they are likely essential for
RNA recognition and interaction in all coronavirus N proteins.
In addition, the structure of the N-NTD in the AMP co-
complex is essentially identical to the previously published
structure of apo HCoV-OC43 N-NTD with a root-mean-
square deviation (RMSD) value of 0.19 Å (123 equivalent Cα
atoms) (Figure 2D). Only the phenyl group of F57 is displaced
backward by 1 Å to prevent steric hindrance at the AMP
entrance. We solved the structures of three additional HCoV-
OC43 N-NTD complexes (cytosine monophosphate (CMP),
guanosine monophosphate (GMP), and uridine monophos-
phate (UMP)), all featured protein−RNA interactions similar
to the interaction of the HCoV-OC43 N-NTD−AMP complex.
See Figure S3 in the Supporting Information. A comparison of
the amino acid composition of ribonucleoside 5′-mono-
phosphate-binding sites in the HCoV-OC43 N-NTD com-
plexes (Figure S3D) shows that amino acid residues Ser 64, Phe
66, Gly 68, Arg 122, Tyr 124, Tyr 126, and Arg 164 are
interactive in more than two HCoV-OC43 N-NTD complex
structures, indicating their importance in RNA binding.
Compared to AMP, the higher B-factors of CMP, GMP, and
UMP indicate the ligand for CMP, GMP, and UMP is quite
ﬂexible in the ribonucleotide-binding pocket of HCoV-OC43
N-NTD (Table 1; Table S1, Supporting Information). On the
basis of the electron density maps of similar resolution data, it
appeared that the structure of the AMP complex showed better
deﬁned electron density for all components of the nucleotide
(Figure 2A). These results suggest that this pocket is probably
speciﬁc for AMP. More studies are needed to prove this in the
future.
RNA-Binding Activity Analyses of Wild-Type and
Mutant HCoV-OC43 N Proteins. We replaced amino acid
residues Arg 122, Tyr 124, Tyr 126, and Arg 164 with alanine
and used surface plasmon resonance (SPR) analysis to
determine their interactions in the binding between the full-
length HCoV-OC43 NPs and RNA. Depending on the virus
strain, there are two to four UCUAA pentanucleotide repeats,
with the last repeat being UCUAAAC and termed the
intergenic (IG) sequence at the 3′ end of the leader.29,30
Previous studies showed that HCoV N protein has high aﬃnity
for the intergenic sequence.11,31 Therefore, the repeated
intergenic sequence of HCoV-OC43, 5′-bio(UCUAAAC)4-3′,
was used as a probe in our SPR experiments. The association
constants, Kd (kd/ka), for the various HCoV-OC43 N protein
and RNA complexes were obtained from kinetic analyses of
SPR experiments (Table 2). The dissociation constants for
RNA binding to R122A, Y124A, Y126A, and R164A range from
3.83 × 10−8 to 8.13 × 10−8 M and are much larger than those
for the wild type (WT). Thus, we identiﬁed several amino acids
in the HCoV-OC43 N protein that are important for RNA
binding, especially R122, Y124, and R164. Previously, Keane et
al. reported that R127 and Y127 in MHV, which correspond to
R122 and Y124 in HCoV-OC43, play key roles in RNA
binding.23,26,27 In addition, the alanine substitution of Y94 in
the NTD of the IBV N protein, which corresponds to Y126 in
HCoV-OC43, led to a signiﬁcant decrease in its RNA-binding
aﬃnity. These results are consistent with our observations.
Since R122A, Y124A, and R164A mutants have signiﬁcant
eﬀects on the RNA-binding activity of the N protein, we
monitored levels of viral RNA encoding the M protein to
determine the eﬀects of R122A, Y124A, and R164A mutants on
the viral replication. Because all OC43 genes are transcribed
concordantly throughout HCoV-OC43 infection, levels of the
M protein gene should reﬂect virus replication. Therefore,
293T cells were transfected with plasmids encoding the mutant
N protein and its WT counterpart followed by infection with
HCoV-OC43. As shown in Figure S4 (Supporting Informa-
tion), in cells transfected with plasmids encoding the mutant N
protein and infected with virus, levels of M RNA were
signiﬁcantly decreased compared to those detected in cells
transfected with plasmids encoding the WT N protein. These
results support the notion that these amino acids of HCoV-
OC43 are important for RNA-binding aﬃnity.
Eﬀect of PJ34 on Virus Replication and the RNA-
Binding Aﬃnity of the N Protein. Next, a virtual screening
was performed, targeting the AMP-binding site of N-NTD.
Potential hits with high docking scores (87 compounds) (Table
S2, Supporting Information) were further analyzed on the basis
of these docking results. We found that nine of the potential
hits showed interaction characteristics reminiscent of those
between AMP and HCoV-OC43 N-NTD (Table S3,
Supporting Information). First, they all contain an aromatic
core able to stack onto Y124 of the N-NTD. Second, the
aromatic core contains hydrogen-bond-forming moieties to
mediate the speciﬁc interactions with the N-NTD. Third, the
aromatic core contains an attached branching moiety (or
moieties) to ﬁt into the ribonucleotide-binding pocket. More
importantly, among the 87 potential hits, these 9 compounds
were readily available commercially. We further studied the
eﬀects of the nine compounds on the RNA-binding capacity of
N protein by SPR experiments. Two compounds, O3 and PJ34,
decreased the RNA-binding capacity of N protein by more than
10% (Table S3). Because PJ34 and O3 were predicted to bind
to the N-NTD ribonucleotide-binding pocket, we next studied
PJ34 and O3 in virus replication assays. To enhance virus
replication, we transfected N cDNA into cells prior to infection
Table 2. Numerical Kd Values
a Obtained from the Kinetic
Analysis of the SPR Experiments Examining Binding of
HCoV-OC43 WT and Mutant N Proteins to RNA
Kd (10
−8 M) Kd (10
−8 M)
wild type 1.17 ± 0.08 Y124A 8.13 ± 0.59
R122A 7.19 ± 0.57 Y126A 3.83 ± 0.25
R164A 7.09 ± 0.45
aKd value obtained from kd divided by ka.
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because previous results showed that increased N protein
expression enhanced replication.20 In general, a 10 μM
concentration of each candidate compound was used in
subsequent assays. If the candidate compound at this
concentration was eﬀective, we considered the compound
worthy of continued development. We monitored M mRNA
levels in infected 293T cells in the presence of PJ34 and O3 at
10 μM both with and without exogenous N protein expression.
Because the M gene is transcribed throughout the HCoV-
OC43 infection, M mRNA levels should reﬂect viral replication.
As predicted from previous studies, M mRNA levels were
increased 7-fold in infected cells transfected with plasmid that
encodes the WT N protein compared to those that did not
receive transfected N cDNA (2.41 and 0.32 in the presence and
absence of N protein expression, respectively) (Figure 3A,B).
In the PJ34-treated cells, M mRNA levels were 0.65 and 0.11 in
the presence and absence of N protein expression, respectively,
while in the O3-treated cells, corresponding M mRNA levels
were 2.46 and 0.22. Thus, M mRNA levels were reduced both
in the presence and in the absence of N protein expression after
Figure 3. Virus replication is inhibited by PJ34 with (A) and without (B) exogenous wild-type HCoV-OC43 N protein expression. (A) Cells were
transfected with a plasmid, pcDNA3.1, encoding the WT N protein or not (B) prior to being infected with HCoV-OC43 as described in the
Experimental Section. The samples were subsequently analyzed for their matrix protein (MP) gene transcript levels in the vehicle-treated, PJ34-
treated, and O3-treated cells. (B) No transfection. Quantitative data are reported as the means ± SD, n = 3. (C) Sensorgram of the interaction
between the immobilized single-stranded RNA and full-length HCoV-OC43 N proteins in the presence of PJ34 at 10 μM. (D) Kinetic analyses
expressed as the dissociation constants for HCoV-OC43 N proteins binding to RNA with and without PJ34. The N protein:drug molar ratio was
1:100.
Figure 4. (A) Chemical structure of PJ34. Structural overview of the HCoV-OC43 N-NTD−PJ34 complex. (B) Unbiased diﬀerence electron density
of PJ34 contoured at 2.9σ. (C) Ribbon representation of the HCoV-OC43 N-NTD with PJ34 depicted as a stick model. (D) Electrostatic surface of
the HCoV-OC43 N-NTD−PJ34 complex. Blue denotes positive charge potential, while red indicates negative charge potential.
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treatment with PJ34 at 10 μM (Figure 3A,B), whereas O3
treatment was not eﬀective. PJ34 has been shown to have
therapeutic eﬃcacy in several noninfectious conditions. In one
instance, PJ34 treatment reduced central nervous system
inﬂammation and maintained neurovascular integrity in mice
during the onset of experimental allergic encephalomyelitis.32
This compound also exhibited neuroprotective eﬀects in both
in vivo and in vitro stroke models.33 To determine whether
PJ34 hindered the HCoV-OC43 replication by interfering with
the binding of the N protein to RNA, we used SPR to
determine the eﬀect of compound PJ34 on the RNA-binding
aﬃnity toward HCoV-OC43 N protein. In the presence of PJ34
under saturation conditions, RNA aﬃnity for HCoV-OC43 NP
decreased with decreasing resonance unit (RU) values for PJ34
(Figure 3C). The HCoV-OC43 N protein exhibited weaker
RNA binding in the presence of PJ34 with a 5-fold increase in
the dissociation constant (Figure 3D). Therefore, PJ34
antagonizes the binding activity between HCoV-OC43 N
protein and RNA. Consequently, the data indicate that PJ34
interacts with the HCoV-OC43 N protein, decreasing RNA
binding and subsequently decreasing viral replication.
Crystal Structure of HCoV-OC43 N-NTD Complexed
with PJ34. To determine the mechanism of PJ34 (Figure 4A)
binding to the HCoV-OC43 N protein, N-NTD crystals were
soaked in PJ34 under the conditions described in the
Experimental Section. We used molecular replacement to
resolve the HCoV-OC43 N-NTD−PJ34 complex structure at a
2.65 Å resolution and reﬁned this model to an Rwork:Rfree ratio
of 18%:22% (Table 1). The complex revealed additional
unbiased density around the ribonucleotide-binding pocket of
the N-NTD, suggesting that the aﬃnity of N-NTD for PJ34
was suﬃciently high to inhibit the RNA-binding aﬃnity of N
protein (Figure 4B). As with the HCoV-OC43 N-NTD−AMP
complex, one PJ34-binding site was noted near the β2 and β3
strands (Figure 4C). The complex adopted a U-shaped β
platform that contained ﬁve β strands across the structure and
resembled the N protein NTDs in other CoVs.23−26 On the
basis of the surface charge distribution, the polycyclic ring of
PJ34 intercalates into the N-NTD hole parallel to the long axis
of the protein structure (Figure 4D).
Parts A and B of Figure 5 reveal the detailed interactions with
PJ34. The amino acid composition of this binding site includes
Ser 64, Phe 66, Tyr 124, Tyr 126, and His 104. The NH
functionalities from the backbone amide groups on Ser 64 are
3.3 Å from the carbonyl group on the PJ34 6-phenanthridinone
ring, indicating that a hydrogen bond may form between Ser 64
and PJ34. Hydrogen bonds also form between the 6-
phenanthridinone ring and the backbone carbonyl group of
Phe 66 via water molecules. The nitrogen atom in the PJ34 6-
phenanthridinone ring also forms a single hydrogen bond with
the Tyr 126 side chain of the HCoV-OC43 N-NTD with a
distance of 2.9 Å. The aromatic ring on the PJ34 6-
phenanthridinone participates in stacking interactions with
the His 104 and Tyr 124 side chains. A comparison between
the N-NTD in both its native and PJ34-complexed forms
generated a low RMSD of 0.20 Å, indicating that binding with
PJ34 requires no signiﬁcant conformational change in the N-
NTD (Figure 5C). The key PJ34-interactive residues of the
native and complexed forms superimpose well; however, the
phenyl group on the Phe 57 side chain in the N-NTD−PJ34
complex rotates over 90°, and the imidazole side group of His
104 moves back 0.8 Å to avoid steric hindrances and to
accommodate PJ34.
Comparison of Crystal Structures of HCoV-OC43 N-
NTD Complexed with PJ34 and AMP. Comparison of the
PJ34- and AMP-bound HCoV-OC43 N-NTD crystal structures
demonstrates that PJ34 and AMP target the same pocket within
HCoV-OC43 N-NTD. Although the HCoV-OC43 N-NTD−
PJ34 and HCoV-OC43 N-NTD−AMP crystal structures
superimpose with a low RMSD of 0.21 Å, the PJ34-binding
orientation diﬀers from that of AMP. PJ34 binds more closely
to the N-terminus loop of the HCoV-OC43 N-NTD than does
AMP, with the Phe 57 side chain rotating 90° counterclockwise
upon PJ34 binding, compared to that of the AMP-bound
HCoV-OC43 N-NTD. The branch moiety of PJ34 inserts into
an interior core of N-NTD that is opposite the ribose moiety of
AMP coming from the inside out. PJ34 also lacks a phosphate
group and fails to match AMP’s interactions with the positively
charged Arg 122 (Figure S5, Supporting Information).
Nevertheless, several of the examined interactions between
the N-NTD and PJ34 were similar to those between N-NTD
and AMP, particularly those with Ser 64, Tyr 124, and Tyr 126
(Figures 2C and 5B).
■ DISCUSSION
The N protein is the most abundant viral polypeptide in CoV-
infected cells and is responsible for recognizing RNA and
forming a ﬁlamentous nucleocapsid.18 Because CoVs are
Figure 5. Crystal structure of the HCoV-OC43 N-NTD complexed
with PJ34. (A) Detailed stereoview of the interactions at the PJ34-
binding site. The PJ34 molecule binds to this site via Ser 64, Phe 66,
His 104, Tyr 124, and Tyr 126. The dotted green lines denote
hydrogen bonds. The red dashed lines indicate van der Waals
interactions. (B) Schematic diagram of PJ34 bound to HCoV-OC43
N-NTD. The hydrogen-bonding interactions mediated by the side-
and main-chain atoms are marked as solid and dashed green lines,
respectively. The van der Waals interactions mediated by the side-
chain atoms are denoted as blue dashed lines. The stacking
interactions mediated by the side-chain atoms are marked as solid
orange lines. (C) Structural superimposition of the native HCoV-
OC43 N-NTD (green) with HCoV-OC43 N-NTD−PJ34 (cyan) at
the residues involved in PJ34 binding.
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signiﬁcant threats to both humans and domestic animals,
understanding the molecular mechanisms governing RNP
formation may facilitate better management of CoV infections.
Previous X-ray analysis revealed that the folding of the N
protein’s N-terminal domain is essentially conserved across
various CoV strains20,24,26,34 with a right-handed ﬁst-shaped
structure in which the palm and ﬁnger are rich in basic residues,
while the ﬂexible loops remain ordered around the β-sheet core
of the NTD, possibly providing a scaﬀold for RNA binding. X-
ray diﬀraction analyses of RNA-binding proteins complexed
with ribonucleoside monophosphate have been used in several
studies to identify the unique ribonucleotide-binding site in the
RNA-binding domain.35,36 Here, we report an N-NTD−
ribonucleoside 5′-monophosphate complex crystal structure
that comprises a pocket for accommodation of ribonucleotide
binding. On the basis of the structures of the N-NTD−
ribonucleotide complex, two tyrosine residues on HCoV-OC43
NTD (Tyr 124 and Tyr 126) were found to interact with RNA
bases via stacking and hydrogen-bonding interactions,
respectively. Similar interactions were observed in complexes
between vesicular stomatitis virus nucleoprotein and RNA.37 In
addition, two arginine residues of HCoV-OC43 NTD, Arg 122
and Arg 164, interact with the phosphate group and ribose
though ionic and hydrogen-bonding interactions, respectively.
These four residues were conserved in other HCoVs as well,
and the results suggest that the ribonucleotide-binding pocket
of the HCoV N-NTD exists among diﬀerent CoVs (Figure S6,
Supporting Information). No structural data are available
regarding CoV N protein binding to single-stranded RNA. To
understand the structural interactions responsible for the RNA
recognition by HCoV-OC43 N-NTD, we modeled the
structure of HCoV-OC43 N-NTD in an RNA-bound state
using the crystal structure of the N-NTD−AMP complex as a
template (Figure S7, Supporting Information). Previous studies
indicated that the positively charged amino acid, Arg 106,
located at the cleft in the HCoV-OC43 N-NTD structure, is
conserved in all CoV N proteins and interacts nonspeciﬁcally
with the RNA phosphate backbone.20 This model indicates that
the RNA-binding region of the N-NTD contains Arg 106, Arg
122, Tyr 124, Tyr 126, and Arg 164 and expands from the β-
sheet core to the exterior loop region. A previous study showed
that other conserved positively charged residues in the
positively charged loop of HCoV-OC43 N protein, including
R107, K110, and R117, were also involved in RNA binding.20
Current antiviral drugs developed to treat CoV infections
primarily target the 3C-like (3CL) and papain-like (PLP)
proteases.38 However, antiviral protease inhibitors may non-
speciﬁcally act on the cellular homologous protease, resulting in
host cell toxicity and severe side eﬀects. Therefore, novel
antiviral strategies are needed to combat acute respiratory
infections caused by CoV. The CoV nucleocapsid protein is a
multifunctional RNA-binding protein that is necessary for viral
RNA transcription and replication. Recent studies suggest that
N proteins in infections caused by coronaviruses and other
viruses will be useful antiviral drug targets because they serve
many critical functions during the viral life cycle. Two strategies
to inhibit oligomeric N protein function have been reported.39
The ﬁrst strategy is to impair normal N protein function by
interfering with monomer−oligomer equilibrium through
either enhancement or inhibition of its oligomerization. The
second one is to target the RNA-binding site, which contains a
number of conserved residues. In one study, nuclozin analogues
were shown to inhibit inﬂuenza A virus replication by
preventing RNP formation during viral particle production.40
Lo et al. identiﬁed an antiviral peptide that interferes with the
CTD oligomerization of the HCoV N protein and inhibits
HCoV.19 The results presented herein provide a detailed, high-
resolution picture of the ribonucleotide monophosphate bound
to the CoV N-NTD and identify a unique ribonucleotide-
binding pocket in the center of the CoV N-NTD. Mutation of
RNA-binding residues in the NTD of the coronaviral N protein
led to a signiﬁcant decrease in its RNA-binding aﬃnity and
subsequent decrease in viral replication. Therefore, the N-
terminal RNA-binding domain of coronaviral N protein would
be a validated target for broad-spectrum antiviral drugs through
interference with the RNA-binding activity of the N protein.
Compounds binding to this site that act as competitive N
protein inhibitors may be employed to combat highly
pathogenic CoVs. PJ34 has been reported to protect mice
against brain ischemia, splanchnic ischemia, reperfusion, and
lipopolysaccharide (LPS) toxicity, in addition to various models
of local inﬂammation.41 We also found that the cell viability was
not aﬀected by treatment with PJ34 alone up to 20 μM for 24 h
in cell lines. Therefore, the eﬃcacy of PJ34 is relatively diverse
while its safety is high, making PJ34 an ideal new candidate for
antiviral therapy. We found that PJ34 at 10 μM inhibits
coronavirus replication and potently interferes with the RNA-
binding activity of HCoV OC43 N protein by targeting the N-
NTD ribonucleotide-binding pocket. On the other hand, O3
did not abolish HCoV-OC43 viral replication, likely because
O3 is closer to the HCoV-OC43 N-NTD disordered loop than
is AMP, which hinders any orientation suitable for the
formation of a hydrogen bond network with the β1 strand,
based on the docking results. Moreover, since O3 is as a potent
inhibitor of CDC25 protein phosphatases,42,43 most likely some
O3 molecules will bind CDC25 and consequently lose the
ability to inhibit HCoV-OC43 N-NTD interactions. On the
basis of the mechanisms of action of compounds such as AMP
and PJ34 and the chemical features common to these two
distinct compound classes, we formulated three general
guidelines for developing CoV N-NTD-targeting agents: First,
a polycyclic aromatic core is required to enable π−π stacking
with the tyrosine residues in the N-NTD. Second, introducing
hydrogen-bond-forming moieties to the aromatic core mediates
speciﬁc interactions with the N-NTD. Third, attaching a
branching moiety (or moieties) that ﬁts the ribonucleotide-
binding pocket can enhance the drug aﬃnity and speciﬁcity
(Figure 6).
In summary, we reported the crystal structures of the CoV
N-NTD in complex with ﬁve ligands, AMP, CMP, GMP, UMP,
and PJ34. These structures not only advance our understanding
of the RNA-binding mechanisms of CoV N-NTD and illustrate
the conformational landscapes of drug-binding pockets, but will
also guide the design of novel antiviral agents useful for treating
pathogenic HCoV infections.
■ EXPERIMENTAL SECTION
Chemicals. The drugs and reagents supplied in ≥95.0% purity as
determined by HPLC were purchased from Sigma Chemical Co. (St.
Louis, MO) and used without further puriﬁcation.
Cloning, Protein Expression, and Puriﬁcation. The HCoV-
OC43 N-NTD gene expression and protein puriﬁcation were
performed according to previously described methods.44 The
pET28a/N-NTD construct was transferred into nonauxotrophic
Escherichia coli cells capable of BL21 (DE3) protein expression.
Protein expression was induced by adding IPTG to 1 mM, followed by
incubation at 10 °C for 24 h. After the bacteria were harvested via
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centrifugation (3500g, 30 min, 4 °C), the bacterial pellets were treated
with lysis buﬀer (50 mM Tris-buﬀered saline [pH 7.3], 150 mM NaCl,
and 15 mM imidazole). The soluble proteins were obtained from the
supernatant after centrifugation (15 000 rpm, 30 min, 4 °C). The
HCoV-OC43 N-NTD proteins carrying a His6-tag at their N-termini
were puriﬁed using a Ni−nitrilotriacetic acid (NTA) column
(Novagen) with an elution gradient ranging from 15 to 300 mM
imidazole. Pure fractions were collected and dialyzed against a low-salt
buﬀer. The puriﬁed protein was ﬁnally concentrated using a 3 kDa
cutoﬀ membrane in Amicon ultra-15 centrifugal ﬁlter units (Millipore,
MA) and stored at −80 °C. The protein concentrations were
determined using the Bradford method with Bio-Rad protein assay
reagents.
Crystallization and Data Collection. HCoV-OC43 N-NTD
crystals were grown as previously described:44 The crystallization
solution (2 μL) was mixed with 1.5 μL of puriﬁed protein solution (8
mg mL−1) and 0.5 μL of 40% hexanediol at room temperature (∼298
K) and equilibrated against a 400 μL solution in the well of a
Cryschem plate at 293 K. The crystallization conditions required a 0.5
M succinic acid−phosphate−glycine (SPG) buﬀer at pH 6.0 with 50%
PEG 1500. The crystalline HCoV-OC43 N-NTD−AMP, HCoV-
OC43 N-NTD−CMP, HCoV-OC43 N-NTD−GMP, and HCoV-
OC43 N-NTD−UMP complexes were obtained via cocrystallization
with an HCoV-OC43 N-NTD solution (8 mg/mL) preincubated for
30 min with 2 mM AMP, 5 mM CMP, 2 mM GMP, and 5 mM UMP,
respectively. Crystals of the HCoV-OC43 N-NTD−PJ34 complex
were obtained by soaking a native HCoV-OC43 N-NTD crystal for 1.5
h at 4 °C in a solution containing 5 mM PJ34 in 0.25 M SPG buﬀer at
pH 6.0 and 25% PEG 1500. The crystals were ﬂash-cooled under
ﬂowing nitrogen gas at 100 K. The X-ray diﬀraction data for the
HCoV-OC43 N-NTD were collected at the National Synchrotron
Radiation Research Centre (NSRRC; Hsinchu, Taiwan), BL13B1. All
diﬀraction images were recorded using an ADSD Q315 charge-
coupled device (CCD) detector, and the data were processed and
scaled using the HKL2000 software package.45 The data collection
statistics of HCoV-OC43 N-NTD complexed with ligand are
summarized in Table 1 and Table S1 in the Supporting Information.
Structural Determination and Reﬁnement. The structures of
the HCoV-OC43 N-NTD complexes with ribonucleoside 5′-mono-
phosphates or PJ34 were determined using the previously resolved
structure of the native HCoV-OC43 N-NTD (3J3K)20 because the
new crystals were isomorphic. For each structure, iterative cycles of
model building were performed using Miﬁt and computational
reﬁnement via CNS and PHENIX;46,47 5% reﬂections were set aside
for the Rfree calculations (Table 1 and Table S1 in the Supporting
Information).48 The stereochemical quality of the structures was
assessed using the PROCHECK program.49 The molecular ﬁgures
were produced using PyMOL (DeLano Scientiﬁc, http://www.pymol.
org).
Drug Discovery of the N Protein Inhibitor. For drug screening,
the HCoV-OC43 N-NTD−AMP complex crystal structure was used
as a template, and a large-scale molecular-docking-based library screen
was conducted to identify compounds that might bind to the AMP-
binding site on the N proteins. Several commercial drug databanks,
including Acros Organics, Sigma Aldrich Inc., and Bachem Inc. from
the ZINC databases, were screened to obtain compounds that act on
the N protein by using the LIBDOCK molecular docking software.
The N protein’s binding pocket was represented using a set of spheres,
and each compound in the database was docked in the important
pocket of the N protein; this pocket included Tyr 124, Tyr 126, Arg
122, and Arg 164 because they are involved in optimal RNA binding.
We identiﬁed 87 potential compounds with high docking scores. Nine
of the potential hits were identiﬁed among the 87 hits that include
three interaction characters with HCoV-OC43 N-NTD, which are
similar to the interactions between AMP and HCoV-OC43 N-NTD.
Site-Directed Mutagenesis. The single mutants were constructed
using a QuikChange kit (Stratagene) with a plasmid containing an
open reading frame that encodes the full-length HCoV-OC43 N
protein as the template for mutagenesis. The PCR reaction used Pfu
DNA polymerase, and each cycle involved heating the sample at 95 °C
for 30 s, 55 °C for 1 min, and 68 °C for 2 min/kb of plasmid length;
this sequence was repeated for a total of 16 cycles. The templates were
digested with DpnI and transformed into E. coli XL-1 cells. All
mutations were conﬁrmed by automated sequencing in both
directions.
SPR Binding Experiments. SPR experiments were performed as
previously described.50 The aﬃnity, association, and dissociation
between the HCoV-OC43 N proteins and RNA were measured using
a BIAcore 3000A SPR instrument (Pharmacia, Uppsala, Sweden)
equipped with a SensorChip SA5 from Pharmacia; the refractive index
change of the sensor chip surface was monitored. These changes are
proportional to the quantity of analyte bound. The change in SPR
angle is reported in resonance units. First, the surface was washed
three times by injecting 10 μL of a 100 mM NaCl solution with 50
mM NaOH. To control the quantity of RNA (or DNA) bound to the
SA chip surface, the biotinylated oligomer was manually immobilized
onto the surface of a streptavidin chip. The chip surface was
subsequently washed with 10 μL of 10 mM HCl to eliminate
nonspeciﬁc binding. The N proteins (WT and mutants) were
dissolved in 50 mM Tris (pH 7.3) with 150 mM NaCl and 0.1%
CHAPS prior to passing over the chip surface for 140 s at 30 μL/min
to achieve equilibrium. Next, a blank buﬀer solution was passed over
the chip to initiate the dissociation reaction; this step was continued
for an additional 600 s, allowing the reaction to reach completion.
After 600 s, the surface was recovered by washing with 10 μL of 0.1%
SDS for each single-stranded RNA. The sensorgrams revealing
interactions between the RNA and protein were analyzed using BIA
evaluation software (version 3) to determine the dissociation constants
(kd/ka). To analyze the eﬀect of PJ34 on the interactions between the
N proteins and RNA, the N proteins were used with PJ34 in 50 mM
Tris (pH 7.5), 150 mM NaCl, and 0.1% CHAPS injected onto the
sensor chip.
Viral Infection and Real-Time Polymerase Chain Reaction
(RT-PCR). An RT-PCR was performed as previously described.51 First,
the 293T cells were cultured in DMEM culture medium containing
10% fetal bovine serum (FBS; Atlanta Biologicals), 1% nonessential
amino acid (NEAA; Invitrogen), and 10 μM β-mercaptoethanol (β-
ME). Then 3 × 105 293T cells were seeded into each well of a 12-well
plate one day prior to transfection. During the viral replication assay,
the cells were transfected or not with pcDNA3.1/NP (WT and
mutants) containing FuGENE 6 (Roche). Four days postinfection, the
media were removed, the cells were lysed in 1 mL of Trisol
(Invitrogen), the RNA was extracted following the manufacturer’s
instructions, and 2 μg of the RNA was used as a template for the
cDNA synthesis. The cDNA (2 μL) was added to 23 μL of a PCR
cocktail containing 2 × SYBR Green Master Mix (ABI, Foster City,
Figure 6. Three general guidelines deduced from the molecular
structures of PJ34 and AMP.
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CA) and a 0.2 μM concentration of both the sense and antisense
primers (IDT DNA, Coralville, IA). The ampliﬁcation was performed
in an ABI Prism 7700 thermocycler (ABI). The speciﬁcity of the
ampliﬁcation was conﬁrmed via dissociation curve analysis. The data
were collected and recorded using the ABI Prism 7700 software and
expressed as a function of the threshold cycle (Ct); the threshold cycle
describes the ﬂuorescence intensity in a given reaction tube as it rises
above the background level (calculated as 10 times the mean standard
deviation of the ﬂuorescence in all wells over the baseline cycles). The
speciﬁc primers used to assay the expression of OC43 M and the
housekeeping gene GAPDH were Fwd-ATGTTAGGCCGATAA-
TTGAGGACTAT, Rev-AATGTAAAGATGGCCGCGTAT and
Fwd-CCACTCCTCCACCTTTGA, Rev-ACCCTGTTGCTGTAG-
CCA, respectively.
HCoV-OC43 N-NTD−ssRNA Complex Modeling. We used the
crystal structure of the N-NTD−AMP complex as a template to
construct a plausible N-NTD−ssRNA complex using the molecular
modeling programs Discovery Studio 2.5 and CNS.46 On the basis of
the N-NTD−AMP complex crystal structure, we extended three and
one nucleotide(s) from the 5′ and 3′ ends of the AMP, respectively,
using the biopolymer module of Discovery Studio 2.5. The complex
structure was further reﬁned using CNS. The RNA force ﬁeld
parameters of Parkinson et al. were utilized.52 The quality of the model
geometry was evaluated using the RMS derivation of the bond length
and bond angle.
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